A randomised placebo controlled clinical trial on the efficacy of Caralluma fimbriata supplement for reducing anxiety and stress in healthy adults over eight weeks.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Anxiety and stress were measured at baseline, week 4, and week 8 to investigate the timing of treatment effect using the GAD-7, Perceived Stress Scale (PSS), Positive and Negative Affect Schedule (PANAS), and salivary cortisol.

Self-reported instruments involve subjective interpretation thus salivary cortisol was employed as a more objective measure.

Who Took Part

The study group was 97 adults.

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the adults and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Data were analysed using mixed ANOVAs on SPSS v.24.

What Was Measured

Topics PubMed links to this paper include Anxiety Disorders, Apocynaceae, Hydrocortisone, Hypothalamo-Hypophyseal System, Phytotherapy, Pituitary-Adrenal System and Plant Extracts.

The authors tagged it with the keywords Caralluma, Complementary therapy, Cortisol, HPA axis, Pregnane glycosides and Stress.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 97 adults.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Journal of affective disorders), a journal based in Netherlands.

More context: the Copper (Supplement) compound page, all human trials.